| Eurand received U.S. FDA approval during Q3 for lead proprietary product ZENPEP, or pancrelipase, Delayed-Release Capsules, a pancreatic enzyme product (PEP) for the treatment of exocrine pancreatic insufficiency, or EPI, due to cystic fibrosis or other conditions; launch is expected to commence by the end of November 2009. :theflyonthewall.com |
